A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

British Journal of Haematology

Volumn 156, Issue 3, 2012, Pages 326-333

  Khan, Meaghan L ^a   Reeder, Craig B ^a   Kumar, Shaji K ^b   Lacy, Marthy Q ^b   Reece, Donna E ^c   Dispenzieri, Angela ^b   Gertz, Morie A ^b   Greipp, Phillip ^b   Hayman, Suzanne ^b   Zeldenhurst, Steven ^b   Dingli, David ^b   Lust, John ^b   Russell, Stephen ^b   Laumann, Kristina M ^b   Mikhael, Joseph R ^a   Leif Bergsagel, P ^a   Fonseca, Rafael ^a   Vincent Rajkumar, S ^b   Keith Stewart, A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bortezomib; Cyclophosphamide; Lenalidomide; Multiple myeloma

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; DRUG SAFETY; FATIGUE; GENETIC RISK; HIGH RISK PATIENT; HUMAN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84855757851     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08949.x     Document Type: Article

References (25)

1. Barlogie, B., Tricot, G.J., van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J.D., Jagannath, S., Bolejack, V., Gurley, J., Hoering, A., Vesole, D., Desikan, R., Siegel, D., Mehta, J., Singhal, S., Munshi, N.C., Dhodapkar, M., Jenkins, B., Attal, M., Harousseau, J. & Crowley, J. (2006) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 135, 158-164.
2. Blansfield, J.A., Caragacianu, D., Alexander, H.R., Tangrea, M.A., Morita, S.Y., Lorang, D., Schafer, P., Muller, G., Stirling, D., Royal, R.E. & Libutti, S.K. (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clinical Cancer Research, 14, 270-280.
3. Brenner, H., Gondos, A. & Pulte, D. (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood, 111, 2125-2126.
4. Gay, F., Hayman, S.R., Lacy, M.Q., Buadi, F., Gertz, M.A., Kumar, S., Dispenzieri, A., Mikhael, J.R., Bergsagel, P.L., Dingli, D., Reeder, C.B., Lust, J.A., Russell, S.J., Roy, V., Zeldenrust, S.R., Witzig, T.E., Fonseca, R., Kyle, R.A., Greipp, P.R., Stewart, A.K. & Rajkumar, S.V. (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood, 115, 1343-1350.
5. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. & Anderson, K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950.
6. Jagannath, S., Durie, B.G., Wolf, J.L., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. & Crowley, J. (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology, 129, 776-783.
7. Jagannath, S., Durie, B.G., Wolf, J.L., Camacho, E.S., Irwin, D., Lutzky, J., McKinley, M., Potts, P., Gabayan, A.E., Mazumder, A., Crowley, J. & Vescio, R. (2009) Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology, 146, 619-626.
8. Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
9. Kumar, S.K., Hayman, S.R., Buadi, F.K., Lacy, M.Q., Stewart, A.K., Greipp, P.R., Russell, S., Zeldenrust, S., Gertz, M.A., Bergsagel, L., Fonseca, R., Allred, J., Campbell, M., Lust, J.A., Witzig, T.E., Kyle, R.A., Rajkumar, S.V. & Dispenzieri, A. (2007) Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma. Blood, 110, 11. Abstract 190.
10. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
11. Kumar, S., Flinn, I.W., Hari, P.N., Callander, N., Noga, S.J., Stewart, A.K., Glass, J., Raje, N., Rifkin, R.M., Shi, H., Webb, I.J., Richardson, P.G. & Rajkumar, S.V. (2009a) Novel three- and four drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide for newly diagnosed multiple myeloma: encouraging results from the multi-center randomized, phase 2 EVOLUTION study. Blood, 114, 22. Abstract 127.
12. Kumar, S.K., Mikhael, J.R., Buadi, F.K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M.A., Greipp, P.R., Hayman, S.R., Kyle, R.A., Lacy, M.Q., Lust, J.A., Reeder, C.B., Roy, V., Russell, S.J., Short, K.E., Stewart, A.K., Witzig, T.E., Zeldenrust, S.R., Dalton, R.J., Rajkumar, S.V. & Bergsagel, P.L. (2009b) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk Adapted Therapy (mSMART) consensus guidelines. Mayo Clinic Proceedings, 84, 1095-1110.
13. Kyle, R.A. & Rajkumar, S.V. (2004) Multiple Myeloma. New England Journal of Medicine, 351, 1860-1873.
14. Kyle, R.A. & Rajkumar, S.V. (2009) Criteria for diagnosis, staging, risk stratification, and response assessment of multiple myeloma. Leukemia, 23, 3-9.
15. Lacy, M.Q., Gertz, M.A., Dispenzieri, A., Hayman, S.R., Geyer, S., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E., Bergsagel, P.L., Stewart, A.K. & Rajkumar, S.V. (2007) Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clinic Proceedings, 82, 1179-1184.
16. Morgan, G.J., Schey, S.A., Wu, P., Srikanth, M., Phekoo, K.J., Jenner, M. & Davies, F.E. (2007) Lenalidomide (Revlimid) in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. British Journal of Haematology, 137, 268-269.
17. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, R.A., Witzig, T.E. & Gertz, M.A. (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, 4050-4053.
18. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M., Greipp, P.R. & Eastern Cooperative Oncology Group. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-lable randomized controlled trial. Lancet Oncology, 11, 29-37.
19. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N.A., Spong, J.E., Piza, J.G., Zepeda, V.H., Mikhael, J.R., Leis, J.F., Bergsagel, P.L., Fonseca, R. & Stewart, A.K. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia, 23, 1337-1341.
20. Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Laumann, K., Hentz, J., Pirooz, N.A., Piza, J.G., Tiedemann, R., Mikhael, J.R., Bergsagel, P.L., Leis, J.F., Fonseca, R. & Stewart, A.K. (2010) Once- versus twice-weekly boretzomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115, 3416-3417.
21. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063-3067.
22. Richardson, P.G., Lonial, S., Jakubowiak, A.J., Jagannath, S., Raje, N.S., Avigan, D.E., Ghobrial, I., Schlossman, R.L., Mazumder, A., Munshi, N.C., Laubach, J., Vesole, D., Joyce, R., Rosenblatt, J., Xie, W., Doss, D., Warren, D.L., Ittleman, K., Revta, C., Francis, D., Leister, C., Kaster, S., Delaney, C., Lauria, M., Mitsiades, C.S., Hideshima, T., Knight, R., Esseltine, D., Weller, E. & Anderson, K.C. (2009) High response rates and encouraging time-to-event data with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: final results of a phase I/II study. Blood, 114, 22.
23. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G., V.I.S.T.A.Trial. Investigators (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
24. Stewart, A.K., Richardson, P.G. & San-Miguel, J.F. (2009) How I treat multiple myeloma in younger patients. Blood, 114, 5436-5443.
25. The International Myeloma Working Group. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.